Literature DB >> 17452128

Cardiovascular manifestations in Fabry disease: a clinical and echocardiographic study.

Norman Sadick1, Liza Thomas.   

Abstract

This study reviews the clinical and echocardiographic findings in a cohort of Fabry patients (n=12) and compares echocardiographic findings to normal controls. Almost all patients had extracardiac manifestations. Five out of 12 patients had cardiovascular symptoms. Nine out of 12 patients had left ventricular hypertrophy (LVH) on the electrocardiogram (ECG) and one patient had short PR interval. Three patients had epicardial coronary disease. Four patients had 'rat-tail' appearance on left ventriculogram. Six patients who had myocardial biopsy showed extensive vacuolation of the myocytes on light microscopy and concentric, myelinoid lamellar cytoplasmic inclusion bodies on electron microscopy. On echocardiography, LV mass was significantly increased in the Fabry group compared to normal controls. Traditional parameters of diastolic function including peak E velocity, peak A velocity and deceleration time were no different to normal controls. The IVRT was significantly prolonged in the Fabry subjects. The PV atrial reversal duration exceeded that of mitral A wave duration in the Fabry group. The septal E' velocity with Doppler tissue imaging (DTI) was significantly lower in the Fabry group than the normal controls. Fabry disease should be considered in the differential diagnosis in patients with unexplained LVH and late onset hypertrophic cardiomyopathy. Extracardiac manifestations are common.

Entities:  

Mesh:

Year:  2007        PMID: 17452128     DOI: 10.1016/j.hlc.2007.03.007

Source DB:  PubMed          Journal:  Heart Lung Circ        ISSN: 1443-9506            Impact factor:   2.975


  6 in total

1.  Identification and functional characterization of the first deep intronic GLA mutation (IVS4+1326C>T) causing renal variant of Fabry disease.

Authors:  Xuantong Dai; Xue Zong; Xiaoxia Pan; Wei Lu; Geng-Ru Jiang; Fujun Lin
Journal:  Orphanet J Rare Dis       Date:  2022-06-20       Impact factor: 4.303

Review 2.  Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment.

Authors:  Brendan N Putko; Kevin Wen; Richard B Thompson; John Mullen; Miriam Shanks; Haran Yogasundaram; Consolato Sergi; Gavin Y Oudit
Journal:  Heart Fail Rev       Date:  2015-03       Impact factor: 4.214

Review 3.  Cardiac abnormalities in Anderson-Fabry disease and Fabry's cardiomyopathy.

Authors:  R P Morrissey; K J Philip; E R Schwarz
Journal:  Cardiovasc J Afr       Date:  2011 Jan-Feb       Impact factor: 1.167

4.  Cardiomyopathy and response to enzyme replacement therapy in a male mouse model for Fabry disease.

Authors:  Aurelie Nguyen Dinh Cat; Brigitte Escoubet; Vincent Agrapart; Violaine Griol-Charhbili; Trenton Schoeb; Wenguang Feng; Edgar Jaimes; David G Warnock; Frederic Jaisser
Journal:  PLoS One       Date:  2012-05-04       Impact factor: 3.240

5.  Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatment.

Authors:  Christoph Kampmann; Amandine Perrin; Michael Beck
Journal:  Orphanet J Rare Dis       Date:  2015-09-29       Impact factor: 4.123

6.  Electrocardiographic Characteristics and Their Correlation with Echocardiographic Alterations in Fabry Disease.

Authors:  Matthew Zada; Queenie Lo; Siddharth J Trivedi; Mehmet Harapoz; Anita C Boyd; Kerry Devine; Norman Sadick; Michel C Tchan; Liza Thomas
Journal:  J Cardiovasc Dev Dis       Date:  2022-01-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.